AbbVie Inc. (NYSE:ABBV) Position Boosted by Capital Advisors Inc. OK

Capital Advisors Inc. OK grew its position in AbbVie Inc. (NYSE:ABBV - Free Report) by 3.5% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 346,804 shares of the company's stock after acquiring an additional 11,793 shares during the quarter. AbbVie makes up approximately 1.4% of Capital Advisors Inc. OK's holdings, making the stock its 18th largest position. Capital Advisors Inc. OK's holdings in AbbVie were worth $72,662,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the company. Brighton Jones LLC grew its stake in AbbVie by 17.4% during the 4th quarter. Brighton Jones LLC now owns 22,912 shares of the company's stock worth $4,072,000 after buying an additional 3,401 shares during the last quarter. Revolve Wealth Partners LLC boosted its position in AbbVie by 72.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company's stock worth $1,294,000 after acquiring an additional 3,064 shares during the period. Proficio Capital Partners LLC grew its stake in shares of AbbVie by 50.8% in the fourth quarter. Proficio Capital Partners LLC now owns 6,622 shares of the company's stock worth $1,177,000 after purchasing an additional 2,230 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich increased its holdings in shares of AbbVie by 11.2% during the fourth quarter. Bank Julius Baer & Co. Ltd Zurich now owns 47,581 shares of the company's stock valued at $8,952,000 after purchasing an additional 4,790 shares during the period. Finally, Rialto Wealth Management LLC bought a new stake in shares of AbbVie during the fourth quarter valued at about $193,000. 70.23% of the stock is currently owned by institutional investors.

AbbVie Trading Up 2.3%

NYSE ABBV traded up $4.34 on Thursday, hitting $194.96. 6,044,939 shares of the company were exchanged, compared to its average volume of 6,288,120. The company's 50 day moving average price is $187.10 and its 200-day moving average price is $188.78. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.76 and a quick ratio of 0.64. The firm has a market capitalization of $344.38 billion, a P/E ratio of 82.96, a price-to-earnings-growth ratio of 1.28 and a beta of 0.48. AbbVie Inc. has a twelve month low of $163.81 and a twelve month high of $218.66.

AbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings data on Friday, April 25th. The company reported $2.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.40 by $0.06. AbbVie had a return on equity of 412.03% and a net margin of 7.31%. The firm had revenue of $13.34 billion for the quarter, compared to the consensus estimate of $12.91 billion. During the same quarter in the previous year, the company earned $2.31 EPS. The business's revenue for the quarter was up 8.4% compared to the same quarter last year. Analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 15th. Shareholders of record on Tuesday, July 15th will be paid a dividend of $1.64 per share. The ex-dividend date of this dividend is Tuesday, July 15th. This represents a $6.56 annualized dividend and a yield of 3.36%. AbbVie's dividend payout ratio (DPR) is presently 279.15%.

Analyst Upgrades and Downgrades

ABBV has been the topic of a number of recent analyst reports. Erste Group Bank upgraded shares of AbbVie to a "strong-buy" rating in a research note on Monday, March 17th. Morgan Stanley lifted their price objective on shares of AbbVie from $241.00 to $250.00 and gave the company an "overweight" rating in a research note on Monday, April 28th. The Goldman Sachs Group restated a "neutral" rating and set a $194.00 price objective on shares of AbbVie in a research note on Tuesday, April 8th. BNP Paribas upgraded shares of AbbVie to a "hold" rating in a research note on Thursday, May 8th. Finally, Wall Street Zen cut shares of AbbVie from a "strong-buy" rating to a "buy" rating in a research note on Thursday, May 22nd. Eight research analysts have rated the stock with a hold rating, seventeen have given a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $211.29.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.